The Research Desk
Straight talk on peptides — what the literature actually says, how compounds work, and what researchers are paying attention to.
Every piece is written to give you something useful — not to sell you on something.
What's New
Tirzepatide First-Line Status: ACP Obesity Guidelines 2025
ACP's 2025 guidelines elevate tirzepatide to first-line obesity treatment. We examine dosing protocols, female-specific metabolic considerations, and unanswered questions in reproductive-age cohorts.
Tirzepatide and Lean Muscle Preservation in GLP-1 Research
Tirzepatide shows a modest improvement in lean-to-fat loss ratio versus GLP-1 monotherapy, but absolute muscle loss remains significant and female-specific data are...
dual-action peptidesTirzepatide vs. GLP-1: Why Telehealth Shifts to Dual-Action
Telehealth platforms are adopting tirzepatide and retatrutide for weight loss, citing higher efficacy than GLP-1 monotherapy, but female-specific data and long-term safety...